Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022
November 14 2022 - 07:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that it plans to report its
financial results for its fiscal fourth quarter and full year ended
September 30, 2022 after the U.S. market closes on November 21,
2022. Enanta management will then host a conference call at 4:30
p.m. ET to discuss these results and provide an update on Enanta’s
business, including its research and development pipeline.
Conference Call and Webcast Information The live webcast
can be accessed under "Events & Presentations" in the investors
section of Enanta’s website
https://ir.enanta.com/events-presentations or by clicking here. To
participate by phone, please register for the call here. It is
recommended that participants register a day in advance or at a
minimum of 15 minutes before the call. Once registered,
participants will receive the dial-in information. The archived
webcast will be available on Enanta’s website following the
event.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections. Enanta’s
research and development programs include clinical candidates
currently in development for the following disease targets:
respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and
hepatitis B virus (HBV). Enanta is also conducting research in
human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is part of one of the leading treatment
regimens for curing chronic HCV infection and is sold by AbbVie in
numerous countries under the tradenames MAVYRET® (U.S.) and
MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit
www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221114005150/en/
Media and Investor Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2023 to Apr 2023
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2022 to Apr 2023
